Lipigon Pharmaceuticals AB (publ)
Stockholm Stock ExchangeTotal Valuation
Lipigon Pharmaceuticals AB (publ) carries a market capitalization of 908,901.00, placing it among publicly traded companies globally.
| Market Cap | 908,901.00 |
| Enterprise Value | N/A |
Share Statistics
Lipigon Pharmaceuticals AB (publ) currently has 605.93M shares outstanding.
| Shares Outstanding | 605.93M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.02 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | -0.12 |
| P/OCF Ratio | -0.11 |
Financial Position
Lipigon Pharmaceuticals AB (publ) maintains a current ratio of 3.01, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.01 |
| Quick Ratio | 2.67 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -87.78 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -244.26 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Lipigon Pharmaceuticals AB (publ)'s stock has declined approximately -98.35526% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.06.
| Beta (5Y) | N/A |
| 52-Week Price Change | -98.35526% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.06 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -32.22M, while operating income came in at -32.22M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -32.22M |
| Pretax Income | -32.44M |
| Net Income | -32.44M |
| EBITDA | -32.22M |
| EBIT | -32.22M |
| Earnings Per Share (EPS) | -0.07 |
Balance Sheet
Total book value stands at -156.52M, with working capital of 7.66M providing operational flexibility.
| Cash & Cash Equivalents | 10.21M |
| Total Debt | N/A |
| Net Debt | -10.21M |
| Equity (Book Value) | -156.52M |
| Book Value Per Share | -0.36 |
| Working Capital | 7.66M |
Cash Flow
Lipigon Pharmaceuticals AB (publ) produced -35.77M in operating cash flow over the past twelve months. After subtracting -108,000.00 in capital expenditures, free cash flow totaled -35.88M - equivalent to -0.08 per share.
| Operating Cash Flow | -35.77M |
| Capital Expenditures | -108,000.00 |
| Free Cash Flow | -35.88M |
| FCF Per Share | -0.08 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -907.87 |
| FCF Yield | -856.59 |
Stock Splits
Lipigon Pharmaceuticals AB (publ)'s most recent stock split took place on March 31, 2023 with a 19:23 split ratio.
| Last Split Date | 3/31/2023 |
| Split Ratio | 19:23 |
Scores
Lipigon Pharmaceuticals AB (publ) posts an Altman Z-Score of -26.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -26.45 |